Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Pharmaceuticals, Inc. on October 31, 2013. The filing serves to announce the company's financial results for the third quarter ended September 30, 2013.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the main body text. Investors must refer to the attached earnings press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Risks
The document does not contain specific guidance, outlook, management commentary, or risk factors in the provided text. It includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the specific revenue and net income figures for the third quarter ended September 30, 2013, by reviewing Exhibit 99.1 (Earnings Press Release).
- Confirm any year-over-year or quarter-over-quarter growth rates mentioned in the attached press release.
- Check for any updated forward-looking guidance or operational milestones announced in the press release.
- Note that the financial data in this 8-K is furnished and not technically "filed" under Section 18 of the Exchange Act.